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Eukaryotic cell cycle progression is mediated by phosphory-
lation of protein substrates by cyclin-dependent kinases
(CDKs). A critical substrate of CDKs is the product of the reti-
noblastoma tumor suppressor gene, pRb, which inhibits G1-S
phase cell cycle progression by binding and repressing E2F
transcription factors. CDK-mediated phosphorylation of pRb
alleviates this inhibitory effect to promote G1-S phase cell cy-
cle progression. pRb represses transcription by binding to the
E2F transactivation domain and recruiting the mSin3histone
deacetylase (HDAC) transcriptional repressor complex via
the retinoblastoma-binding protein 1 (RBP1). RBP1 binds to the
pocket region of pRb via an LXCXE motif and to the SAP30
subunit of the mSin3HDAC complex and, thus, acts as a
bridging protein in this multisubunit complex. In the present
study we identified RBP1 as a novel CDK substrate. RBP1 is
phosphorylated by CDK2 on serines 864 and 1007, which are
N- and C-terminal to the LXCXE motif, respectively. CDK2-
mediated phosphorylation of RBP1 or pRb destabilizes their
interaction in vitro, with concurrent phosphorylation of both
proteins leading to their dissociation. Consistent with these
findings, RBP1 phosphorylation is increased during progres-
sion from G1 into S-phase, with a concurrent decrease in its
association with pRb in MCF-7 breast cancer cells. These stud-
ies provide new mechanistic insights into CDK-mediated regu-
lation of the pRb tumor suppressor during cell cycle progres-
sion, demonstrating that CDK-mediated phosphorylation of
both RBP1 and pRb induces their dissociation to mediate re-
lease of the mSin3HDAC transcriptional repressor complex
from pRb to alleviate transcriptional repression of E2F.
The eukaryotic cell cycle is an evolutionarily conserved
process that regulates cell division from unicellular organisms
such as yeast through to humans. In response to developmen-
tal cues, appropriate growth conditions, and stimulation by
mitogenic growth factors, cell division is promoted by activa-
tion of the key enzymes responsible for promoting cell cycle
progression, the cyclin-dependent kinases (CDKs).4 These
dimeric enzymes consist of a cyclin regulatory subunit, which
binds and activates a CDK protein kinase subunit (1). In
mammalian cells, progression through the different cell cycle
phases is mediated by different CDKs. Therefore, cyclin
D/CDK4/6 controls progression through G1 phase (2, 3) fol-
lowed by cyclin E/CDK2 kinase activity promoting G1-S phase
progression (4). Cyclin A/CDK2 is important during S phase
and cyclin A/CDK1 activity peaks during G2 phase (5). Finally,
cyclin B/CDK1 activity is required for mitosis (6, 7). CDKs
mediate cell cycle progression through phosphorylation of
protein substrates to alter their biological function(s). Differ-
ent CDKs phosphorylate distinct substrates to promote pro-
gression through different cell cycle phases due to their differ-
ential temporal activities, substrate specificities, and
subcellular localization, although some substrates are phos-
phorylated by different CDKs whose activities temporally
overlap (8–10).
One important CDK substrate is the retinoblastoma gene
product, pRb, a tumor suppressor protein that controls G1-S
phase cell cycle progression in mammalian cells (11, 12). pRb
inhibits cell cycle progression largely through binding and
inhibition of the E2F family of transcription factors, whose
activity is required for the transcription of genes necessary for
S phase progression (13). pRb inhibits E2F transcriptional
activity by two mechanisms, including binding and inhibition
of the E2F transactivation domain (14), and by recruiting
members of the histone deacetylase (HDAC) family to E2F
promoters (15, 16). HDAC-mediated deacetylation of the core
histones at E2F promoters leads to a tighter association be-
tween core histones and DNA, impairing access of transcrip-
tional co-activators leading to transcriptional inhibition (17).
pRb contains several domains, including a so-called pocket
region as well as N- and C-terminal regions (18–20). The
pocket of pRb is45 kDa, comprising of two domains, A and
B, which are separated by a spacer region. The pRb pocket
domain plays an important role in E2F transcriptional inhibi-
tion, as it is responsible for recruitment of the HDAC multi-
subunit transcriptional repressor complex (21, 22). Although
initial studies suggested that the HDAC complex binds di-
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rectly to pRb (15, 16), subsequent studies demonstrated that
recruitment of this complex to pRb is mediated by the retino-
blastoma-binding protein 1 (RBP1) (22–28). RBP1 binds to
the pRb pocket region via an LXCXE motif (23), which is
present in many pRb-binding proteins (29). RBP1 also binds
the Sin3-associated protein of the 30-kDa (SAP30) subunit,
which in turn binds to the Sin3 scaffolding protein (26). Sin3
binds several subunits (30), including SAP18 (31), SAP45 (32),
retinoblastoma-associated proteins of 46 kDa (RbAP46) and
48 kDa (RbAP48) (21, 31) as well as HDACs. RBP1, thus, acts
as a bridging protein to recruit the mSin3HDAC complex to
pRb to repress E2F-mediated transcription (22, 24, 27, 28).
During G1-S phase cell cycle progression the cumulative
phosphorylation of pRb by cyclin D/CDK4/6 and cyclin E/A/
CDK2 on different sites is necessary to achieve full inactiva-
tion of its repressor function and activation of E2F-mediated
transcription (13, 18, 20, 33–35). Phosphorylation on several
pRb sites leads to disruption of E2F and HDAC binding to
abolish pRb-mediated inhibition of E2F transcription (13, 18,
20, 36).
Previous work in this laboratory has utilized an in vitro
phosphorylation screen of recombinant proteins expressed
from -phage cDNA expression library to identify the ubiq-
uitin conjugating enzyme hHR6A as a novel CDK substrate
(37). The utility of this method for identifying novel sub-
strates of CDKs and other protein kinases has also been vali-
dated by other studies (37–39). In addition to hHR6A, we iso-
lated a protein termed Sin3-associated protein of 180 kDa
(SAP180) as a putative CDK substrate in this screen. SAP180
belongs to the AT-rich interaction domain 4 (ARID4) family
of DNA-binding proteins (25, 40), which binds to the mSin3
transcriptional repressor complex (32) and is referred to as
ARID4B. SAP180 (ARID4B) is closely related to ARID4A,
which is also known as RBP1, sharing 34% identity and 50%
similarity at the amino acid sequence level (27, 32). Due to the
important role of RBP1 (ARID4A) in regulating E2F function
through recruitment of the mSin3HDAC complex to pRb
(24, 41), we investigated if RBP1 is regulated by CDK-medi-
ated phosphorylation.
RBP1 contains a consensus ARID DNA binding sequence
of100 amino acids (residues 314–409), common to other
members of the ARID DNA binding family proteins (40).
RBP1 also possesses a Tudor domain at the N-terminal region
(residues 58–114) as well as a chromatin organization modi-
fier (Chromo) domain (residues 593–633). Tudor domains
facilitate interaction with the methylated lysine residue of
histone H3 (42), whereas Chromo domains, which span be-
tween 30 and 70 amino acids, are found in proteins involved
in the assembly of protein complexes on chromatin (43–45).
RBP1 binds to SAP30 via repressor region 2 (amino acids
1167–1257) to recruit the mSin3HDAC complex and induce
transcriptional repression (22, 24). RBP1 also contains a tran-
scriptional repressor region 1 (amino acids 241 and 542),
which encompasses the ARID domain and induces repression
independent of HDACs through an unknown mechanism
(24).
At a whole animal level, RBP1-deficient mice (Arid4a/)
are viable but display an increased mortality rate (46). RBP1-
deficient mice display an age-related cytopenia and thrombo-
cytopenia and develop myelofibrosis and hepatosplenomegaly
(46). They develop a myelodysplastic/myeloproliferative dis-
order. Approximately 12% of RBP1-deficient mice with my-
elodysplastic/myeloproliferative disorder further developed
acute myeloid leukemia, indicating the functional importance
of RBP1 as murine leukemia suppressor (46).
In the present study we demonstrate that RBP1 is a novel
CDK substrate, which is phosphorylated on serines 864 and
1007. These sites are located N and C terminus to the RBP1
LXCXE pRb binding motif (amino acids 957–961). CDK-me-
diated phosphorylation of RBP1 or pRb reduced their interac-
tion, whereas phosphorylation of both proteins leads to maxi-
mal dissociation. These findings indicate that concurrent
CDK-mediated phosphorylation of RBP1 and pRb underpins
the mechanism for dissociation of the mSin3HDAC tran-
scriptional repressor complex from E2F during cell cycle
progression.
EXPERIMENTAL PROCEDURES
Plasmids, Cell Lines, and Antibodies—Human RBP1 cDNA
was cloned into mammalian pCMV Tag2A (Stratagene), Esch-
erichia coli pGEX 4T-1 (GE Healthcare), and baculovirus
pFastBAC Tri-EX expression vectors. The C-terminal region
of RBP1 was cloned into pGEX4T-1 to generate GST-
RBP1784–1257. Deletion constructs of RBP1 were cloned into
the pET15b (Novagen) to generate His6-RBP1784–930 and
His6-RBP1937–1073.
Human embryo kidney 293 (HEK293), HEK293 with T-
large antigen (HEK293T), and human breast adenocarcinoma
(MCF-7) cell lines were cultured in Dulbecco’s modified ea-
gle’s medium (Sigma) supplemented with 10% fetal bovine
serum (SAFC Bioscience) at 37 °C with 5% CO2. Spodoptera
frugiperda (Sf9) cells were cultured in SF900 II SFM media
(Invitrogen) at 27 °C.
Mouse monoclonal antibodies against FLAG epitope (M2,
Sigma, F1804), Penta-His (Qiagen, 34660), and pRb (Calbio-
chem, OP-66) and rabbit polyclonal antibodies against human
SAP30 (Upstate, 06-875), human mSin3A (AK-11) (Santa
Cruz, sc-767), and goat polyclonal anti-GST antibody (Amer-
sham Biosciences, 27-4577-01) were used according to the
manufacturer’s instructions.
Expression and Purification of Recombinant Proteins—Re-
combinant GST-RBP1, GST-RBP1784–1257, His6-RBP1784–930,
His6-RBP1937–1073, His6-SAP30, and MBP-pRb279–928 were
expressed in E. coli strain Rosetta BL21 (DE3) pLysS (Nova-
gen). Cultures were grown in LB medium containing 100
g/ml ampicillin and 50 g/ml chloramphenicol at 37 °C to
an A600 nm of0.8. GST-RBP1 and GST-RBP1784–1257 pro-
tein expression was induced with 1 mM isopropyl 1-thio--D-
galactopyranoside at either 10 °C for 24 h or room tempera-
ture (RT) for 3 h, respectively, whereas MBP-pRb279–928
expression was induced at RT with 0.4 mM isopropyl 1-thio-
-D-galactopyranoside and 2 g/liter (11 mM) glucose for 3 h.
Cells were lysed in PBS supplemented with 50 g/ml ly-
sozyme, 1% Triton X-100, 10 g/ml aprotinin, 10 g/ml leu-
peptin, and 1 mM PMSF, and proteins were bound to either
glutathione-agarose (Sigma) or amylose resin (New England
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Biolabs). Purification of recombinant proteins was carried out
at 4 °C. The resin was washed extensively with 5 repeats of 1
ml of buffer W (50 mM HEPES, pH 7.5, 150 mM NaCl, 1%
Tween 20, 0.5 mM DTT, 2 mM EDTA, 30 mM NaF, 20 mM
NaPPi, 10 mM -glycerol phosphate, 1 mM Na3VO4, 1 mM
PMSF). GST-RBP1 was eluted with 500 l of glutathione elu-
tion buffer (100 mM HEPES, pH 7.9, 150 mM NaCl, 1 mM
DTT, 10% glycerol, 20 mM L-glutathione, 10 g/ml aprotinin,
10 g/ml leupeptin, 1 mM PMSF), whereas MBP-pRb279–928
was eluted with 500 l of maltose elution buffer (50 mM
HEPES, pH 7.5, 150 mM NaCl, 10% glycerol, 1 mM DTT, 100
mM maltose, 10 g/ml aprotinin, 10 g/ml leupeptin, 1 mM
PMSF). His6-SAP30 expression was induced at RT, whereas
His6-RBP1784–930 and His6-RBP1937–1073 expression was in-
duced at 37 °C with 1 mM isopropyl 1-thio--D-galactopyr-
anoside for 3 h. Cells were lysed with 50 mM Tris-HCl, pH 7.5,
300 mM NaCl, 1% Nonidet P-40, 10 mM -mercaptoethanol,
10 mM imidazole, 50 g/ml lysozyme, 10 g/ml aprotinin, 10
g/ml leupeptin, and 1 mM PMSF. After centrifugation, the
supernatant was incubated with Ni2-nitrilotriacetic acid
resin (Qiagen) at 4 °C overnight. The resin was extensively
washed with lysis buffer, and His6-SAP30 was eluted with 500
l of imidazole elution buffer (50 mM NaH2PO4 pH7.7, 300
mM NaCl, 250 mM imidazole, 10 mM -mercaptoethanol, 10
g/ml aprotinin, 10 g/ml leupeptin, 1 mM PMSF). GST-
RBP1, MBP-pRb279–928, and His6-SAP30 were dialyzed for
three successive rounds against 600 ml of dialysis buffer (50
mM HEPES, pH 7.5, 1 mM DTT, 0.01% Tween 20, 5% glycerol,
0.5 mM PMSF).
For expression of baculoviral GST-RBP1, Sf9 insect cells
(0.5 106 cells/ml) were infected with recombinant baculovi-
ruses coding for GST-RBP1 at 27 °C for 3 days and lysed with
buffer W. GST-RBP1 was purified using glutathione agarose
and then dialyzed as described above.
CDK-mediated Phosphorylation of RBP1 in Vitro and Phos-
phoamino Acid Analysis—Recombinant cyclin/CDKs were
prepared as described previously (8, 37). 2 g of GST-RBP1
purified from Sf-9 insect cells immobilized on 10 l of gluta-
thione-agarose was dephosphorylated by treatment with 140
units of -phosphatase (New England Biolabs) at 30 °C for
1 h. After 3 1-ml washes with buffer W, GST-RBP1 was
phosphorylated by purified cyclin/CDKs in a 30-l volume as
described previously (37, 47). Alternatively, His6-RBP1784–930
and His6-RBP1937–1073 purified on Ni2-nitrilotriacetic acid
resin were phosphorylated with purified cyclin A/CDK2 as
described previously (37, 47). Samples were separated by SDS-
PAGE, stained with Coomassie Brilliant Blue (Bio-Rad), and
visualized by autoradiography. Phosphoamino acid analysis
was performed as described previously (48).
In Vivo [32P]Orthophosphate Labeling of RBP1—FLAG-
RBP1 was expressed in HEK293 cells after transfection with
pCMV Tag2A-RBP1 plasmid using FuGENE HD. 48 h post-
transfection, cells were grown for 4 h in medium containing
0.5 mCi/ml [32P]orthophosphate (MP Biomedicals) in the
absence or presence of the CDK1/CDK2 inhibitor Roscovitine
(50 M) (Calbiochem) (49). Cells were lysed with 600 l of
ice-cold buffer W, syringed with a 25-gauge needle to shear
DNA, and centrifuged at 16,100 g at 4 °C for 15 min, and
FLAG-RBP1 was immunoprecipitated from the supernatant
with 20 l of packed anti-FLAGM2-agarose (Sigma). Phos-
phorylated FLAG-RBP1 was separated by 8% SDS-PAGE and
visualized by autoradiography or transferred to nitrocellulose
before detection by immunoblotting with anti-FLAG
antibody.
Cell Cycle Studies in MCF-7 Breast Cancer Cells—MCF-7
cells were transfected with either pCMV Tag2A or pCMV
Tag2A-RBP1 plasmid and 2 h post-transfection, and cells
were incubated with 10 nM estrogen receptor antagonist ICI
182780 (ICI, Tocris Bioscience) for 24 h to induce G0/G1-
phase cell cycle arrest. The MCF-7 cells were then stimulated
to synchronously re-enter the cell cycle by adding 100 nM
17-estradiol (E2, Sigma), as described previously (41, 50). To
monitor cell cycle progression, cells were collected at 15, 21,
27, 33, and 39 h after treatment with 17-estradiol, fixed with
70% (v/v) ethanol at 4 °C overnight, and stained with 5-bro-
mo-2-deoxyuridine (BrdU) to determine S phase cell popula-
tion. Briefly, 2 h before cell collection, cells were pulsed with 1
g/ml BrdU (Sigma). Once fixed, cells were collected by cen-
trifugation at 500 g 4 °C for 5 min and resuspended in 200
l of ice-cold 0.1% Triton-X-100, 0.1 N HCl, left on ice for 1
min, and centrifuged at 500 g at 4 °C for 5 min. The cell
pellet was washed once with 1 ml of DNA denaturation buffer
(150 M NaCl, 15 M trisodium citrate dihydrate) at 500 g
at RT for 5 min, resuspended in 200 l of DNA denaturation
buffer, and incubated at 90 °C for 5 min. Cells were left on ice
to chill for 5 min, then washed once with 1 ml of freshly pre-
pared antibody diluting buffer (PBS, 0.1% Triton X-100, 1%
(w/v) BSA) and collected by centrifugation at 3000 g RT for
10 min. Cells were stained with 200 ng of FITC-conjugated
anti-BrdU antibody (diluted to 100 l with antibody diluting
buffer) at RT for 30min in the absence of light and analyzed
on FACSCalibur (BD Biosciences).
Mass Spectrometry—FLAG-RBP1 was expressed in HEK293
cells after transfection with pCMV Tag2A-RBP1 plasmid us-
ing FuGENE HD, immunoprecipitated, and separated by
SDS-PAGE, and gel slices containing FLAG-RBP1 were
treated with 0.5 g of trypsin (Promega) (51). Tryptic digests
were dried under vacuum, resuspended in 60% (v/v) acetoni-
trile, 5% (v/v) trifluoroacetic acid, and purified on TiO2 beads
(GL Sciences) using micro-columns. The TiO2 beads were
washed twice with 60 l of 60% (v/v) acetonitrile, 5% (v/v)
trifluoroacetic acid and eluted with 120 l of 1.25% (w/v)
NH4OH (BDH). Purified phosphopeptides were dried under
vacuum, resuspended in 20 l of 2% (v/v) formic acid (Sigma),
and analyzed by LC/MS. Chromatography was performed on
a Dionex Ultimate 3000 nano-LC at a flow rate of 500 nl/min.
Peptides were resolved on a 20-cm 75-m C18 column (LC
Packings Pepmap100 C18 resin) using a 3–35% acetonitrile
gradient. Mass spectrometry was performed on a QSTAR-
pulsar i (Applied Biosystems) using a micro-ion spray source
(Applied Biosystems). Data were acquired using a data-depen-
dent acquisition program and analyzed by MASCOT software
(Matrix Science, supplied by the Australian Proteomics Com-
putational Facility and funded by the Australian National
Health and Medical Research Council Grant 381413). MS/MS
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spectra were manually validated to confirm the accuracy of
assigned phosphorylation sites.
In Vitro RBP1 Binding Studies—10 g of MBP-pRb279–928
was immobilized on 20 l of packed amylose resin in the
presence of 3 mg of BSA in buffer W in a total volume of 400
l. Immobilized MBP-pRb279–928 was either unphosphory-
lated or phosphorylated with cyclin A/CDK2 and extensively
washed with cold buffer W. Immobilized MBP-pRb279–928
was then mixed with 2.5 g of either unphosphorylated or
cyclin A/CDK2 prephosphorylated GST-RBP1 (purified from
E. coli) in a total volume of 30 l at 4 °C for 5 h. As control,
ATP was omitted from the kinase reactions. To assess the
effect of cyclin A/CDK2-mediated phosphorylation on the
association of pre-assembled RBP1 and pRb, 20 g of MBP-
pRb279–928 was immobilized on 40 l of packed amylose resin
as described above and mixed with 5 g of GST-RBP1 to al-
low binding. After extensive washing with 1 ml of buffer W,
the amylose resin with MBP-pRb279–928GST-RBP1 was di-
vided into two equal volumes and was either phosphorylated
with cyclin A/CDK2 in a total volume of 30 l or left unphos-
phorylated. After washing with buffer W, proteins were sepa-
rated by 9% SDS-PAGE and transferred to nitrocellulose for
analysis of the level of bound GST-RBP1 by immunoblotting
using anti-GST antibody.
For GST-RBP1784–1257 binding studies with SAP30, E. coli
lysate expressing GST-RBP1784–1257 was mixed with 15 l of
packed glutathione-agarose. After extensive washing with
buffer W, the glutathione-agarose conjugated GST-
RBP1784–1257 was either left unphosphorylated or phosphor-
ylated with cyclin A/CDK2, washed again, and then mixed
with 10 g of His6-SAP30 in a total volume of 30 l at 4 °C for
5 h. The samples were then extensively washed with buffer W
and subjected to immunoblotting using anti-penta-His anti-
body to detect His6-SAP30. To assess if CDK-mediated phos-
phorylation affects the association of pre-assembled
RBP1SAP30 complex, GST-RBP1784–1257 was immobilized
on glutathione-agarose as described and then mixed with 10
g of His6-SAP30 in a total volume of 30 l at 4 °C for 5 h.
After extensive washing with buffer W, the samples were di-
vided into two equal volumes and were either incubated with
or without cyclin A/CDK2 in a total volume of 30 l under
phosphorylation conditions. The samples were then washed
extensively with buffer W and then subjected to immunoblot-
ting with anti-penta-His antibody to detect His6-SAP30.
Analysis of Cell Cycle-dependent Association of RBP1 with
pRb, SAP30, and mSin3A—MCF-7 cells, transfected with ei-
ther pCMV Tag2A or pCMV Tag2A-RBP1, were arrested in
G0/G1 phase and stimulated to synchronously re-enter the
cell cycle as described under cell cycle studies. FLAG-RBP1
was immunoprecipitated with anti-FLAGM2-agarose from
lysates prepared fromMCF-7 cells arrested in G0/G1 phase or
27 h after E2 addition when cells peaked in S phase. The sam-
ples were separated by SDS-PAGE and subjected to immuno-
blotting with the appropriate antibodies to detect pRb,
SAP30, and mSin3A. All densitometry analyses were per-
formed using the ImageQuant TL software (GE Healthcare).
HDAC Assay—[3H]Acetylated histones were prepared as
described previously (52). To measure HDAC activity, FLAG-
RBP1 immunoprecipitates were incubated in 100 l of HDAC
assay buffer (100 mM HEPES pH7.5, 100 mM NaCl, 0.1 mM
EDTA, 1 mM PMSF) with 1 g of [3H]acetylated histones
(21,400 cpm) in the presence or absence of 3 M HDAC
inhibitor trichostatin A (Cell Signaling) at 37 °C for 1 h. The
reaction was stopped by adding 100 l of 0.1 N HCl, 0.16 N
CH3COOH solution and mixed with 900 l of ethyl acetate.
After centrifugation, the upper, organic layer containing
[3H]acetyl was removed and measured by scintillation count-
ing in a Tri-Carb 2900TR (PerkinElmer Life Sciences).
RESULTS
RBP1 Is a CDK Substrate, Which Is Phosphorylated in a Cell
Cycle-dependent Manner—To identify novel CDK substrates,
we performed phosphorylation screening of a -phage cDNA
expression library with cyclin A/CDK2 in vitro, as described
previously (37). One clone identified in this screen encoded a
partial sequence corresponding to SAP180 (Sin3-associated
protein of 180 kDa). As noted in the introduction, SAP180 is
related to RBP1 (27, 32), which plays a critical role in pRb-
mediated E2F repression by recruiting the mSin3HDAC tran-
scriptional repressor complex (22, 24, 28). Because CDK-me-
diated phosphorylation of pRb is known to inactivate its
inhibitory function toward E2Fs, we investigated if CDK-me-
diated phosphorylation of RBP1 also contributes to the regu-
lation of this complex.
Sequence analysis revealed that RBP1 contains 16 CDK
consensus phosphorylation sites, which consist of a phosphor-
ylated serine or threonine followed by an obligatory C-termi-
nal proline ((S/T)P) (53–55). To investigate if RBP1 is a CDK
substrate, full-length purified recombinant GST-RBP1 was
phosphorylated with purified recombinant cyclin/CDKs in
vitro. GST-RBP1 was phosphorylated by cyclin D1/CDK4,
cyclin E/CDK2, cyclin A/CDK2, cyclin A/CDK1, and cyclin
B/CDK1, as was GST-pRb773–928, which was included as a
positive control (Fig. 1A). We next evaluated if RBP1 is phos-
phorylated in vivo by expressing FLAG-RBP1 in HEK293 cells
in the presence of [32P]orthophosphate. FLAG-RBP1 was
readily phosphorylated in vivo (Fig. 1B). Importantly, the level
of phosphorylation was reduced by40% in the presence of
CDK1 and CDK2 inhibitor Roscovitine (50 M) (49), indicat-
ing that RBP1 phosphorylation is dependent on cyclin/CDK
activity in vivo.
To investigate if RBP1 is phosphorylated in a cell cycle-de-
pendent manner, FLAG-RBP1 was expressed in MCF-7 cells,
which were metabolically labeled with [32P]orthophosphate.
MCF-7 cells are dependent on estrogen for growth and, there-
fore, can be arrested in G0/G1 phase of the cell cycle by the
addition of the estrogen receptor antagonist ICI 182780 (ICI).
The addition of excess of E2 can then be used to stimulate
cells to synchronously reenter the cell cycle (41, 50). To quan-
tify the kinetics of G0/G1-S-phase cell cycle progression by
determining the proportion of cells in S phase, cells were la-
beled with BrdU and analyzed by flow cytometry. Treatment
of cells with ICI 182780 resulted in the arrest of most MCF-7
cells in G0/G1 phase, with only 12% remaining in S phase (Fig.
1C, upper panel), compared with asynchronous cells, which
contained40% of cells in S-phase (data not shown). After
CDK-mediated Phosphorylation of RBP1
FEBRUARY 18, 2011•VOLUME 286•NUMBER 7 JOURNAL OF BIOLOGICAL CHEMISTRY 5111
 at Queensland Univ of Technology (CAUL) on M
ay 11, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
estradiol treatment, cells progressed from G1 into S phase and
peaked at42% S phase 27 h after re-entry into the cell cycle,
and thereafter, the proportion of cells in S phase decreased as
cells progressed into G2/M phase (Fig. 1C, upper panel), simi-
lar to previous reports with this model (50). MCF-7 cells
transfected with empty vector or those expressing ectopic
FLAG-RBP1 displayed similar kinetics of cell cycle progres-
sion (Fig. 1C, upper panel). We repeated this experiment after
labeling cells in the presence of [32P]orthophosphate and im-
munoprecipitated FLAG-RBP1 from cells arrested in G0/G1
phase and 27 h after estradiol addition, when cells peaked in S
phase. Phosphorylation of FLAG-RBP1 increased 2-fold when
cells were in S phase compared with G0/G1 phase (Fig. 1C,
lower panel).
RBP1 Is Phosphorylated on CDK Consensus Site Serines 864
and 1007 in Vivo and in Vitro—We next performed studies to
identify the sites on RBP1 phosphorylated in vitro and in vivo.
For in vitro phosphorylation, we utilized cyclin A/CDK2 be-
cause this cyclin/CDK robustly phosphorylated purified GST-
RBP1 (Fig. 1A), and RBP1 phosphorylation increased as cells
progressed through S phase (Fig. 1C), when A/CDK2 is active.
Furthermore, our previous studies demonstrate that A/CDK2
phosphorylates nearly all the substrates phosphorylated by
E/CDK2, which is the other major cyclin/CDK active during
G1-S phase (8). Phosphoamino acid analysis revealed that
RBP1 was predominantly phosphorylated on the serine resi-
due(s) in vitro by cyclin A/CDK2, whereas 32P-labeled RBP1
purified from HEK293 cells was exclusively phosphorylated
on serine residue(s) (Fig. 2A).
To identify the site(s) on RBP1 phosphorylated in vivo, we
performed tandem mass spectrometry on FLAG-RBP1 immu-
noprecipitated from HEK293 cells. FLAG-RBP1 was phos-
phorylated on three sites, at serine residues 864, 1007, and
1109. Sites 864 with the sequence GQSpSPEK and 1007 with
the sequence SVApSPLT (Fig. 2B) conform to the CDK con-
sensus phosphorylation motif ((S/T)P). Site 1109 with the
sequence GQSpSDSE (Fig. 2B) does not conform to a CDK
consensus phosphorylation site, suggesting that another ki-
nase(s) is responsible for phosphorylation of this site. In
agreement with our findings, phosphorylation of serines 864
and 1109 on endogenous RBP1 has previously been reported
in large-scale phosphoproteomics screens (56, 57). Further-
more, RBP1 serine 864 shows increased phosphorylation dur-
ing G1/S phase and decreases during mitosis, indicating that
phosphorylation of this site is cell cycle-regulated (57), con-
sistent with our findings that phosphorylation of this site is
regulated by CDKs.
Mass spectrometry analysis demonstrated that GST-RBP1
serines 864 and 1007 were also phosphorylated by A/CDK2 in
vitro (data not shown). In addition, cyclin A/CDK2 phosphor-
ylated threonine 1124 and serines 1140 and 1145 in vitro
(data not shown). Threonine 1124 likely accounts for the
small level of phosphothreonine observed in the phos-
phoamino acid analysis (Fig. 2A). Some of these extra sites
phosphorylated by cyclin A/CDK2 in vitromay be inaccessi-
ble for phosphorylation in vivo due to binding to proteins
such as SAP30 (22, 27), which may preclude access of cyclin/
CDKs. To confirm phosphorylation of serines 864 and 1007
by cyclin A/CDK2, we generated two truncated His6-RBP1
constructs, His6-RBP1784–930 and His6-RBP1937–1073, incor-
porating these sites and their corresponding mutants, where
serines 864 and 1007 were mutated to alanine, to generate
His6-RBP1784–930 (S864A) and His6-RBP1937–1073 (S1007A).
Both His6-RBP1784–930 and His6-RBP1937–1073 were
readily phosphorylated by A/CDK2 in vitro, whereas their
respective alanine mutants, His6-RBP1784–930 (S864A) and
His6-RBP1937–1073 (S1007A), showed no phosphorylation (Fig. 2C).
CDK-mediated Phosphorylation of RBP1 Does Not Affect Its
Binding to SAP30 in Vitro—Because RBP1 recruits the
mSin3HDAC complex via the SAP30 subunit to pRb (22, 24,
26–28), we investigated if CDK-mediated phosphorylation of
RBP1 might regulate its binding to SAP30. The C-terminal
region of RBP1 (1167–1257) interacts with SAP30 (22, 27)
(Fig. 2D). We established an in vitro binding assay with re-
combinant GST-RBP1784–1257 and His6-SAP30. First, GST-
RBP1784–1257 was immobilized on glutathione-agarose and
either left unphosphorylated or phosphorylated with cyclin
A/CDK2 before incubation with His6-SAP30. The agarose
beads were then extensively washed before immunoblotting
to assess the level of His6-SAP30 bound. Consistent with pre-
vious studies (22, 24, 26–28), His6-SAP30 specifically inter-
acted with GST-RBP1784–1257 (Fig. 3A, lanes 1 and 2). Cyclin
A/CDK2-mediated phosphorylation of GST-RBP1784–1257 did
not alter the level of His6-SAP30 binding compared with un-
FIGURE 1. RBP1 is phosphorylated by CDKs in vitro and in vivo in a cell
cycle-dependent manner. A, recombinant GST-RBP1 or GST-pRb773–928
were incubated with the indicated cyclin/CDKs in the presence of
[-32P]ATP, separated by SDS-PAGE, and analyzed by autoradiography.
B, FLAG-RBP1 was immunoprecipitated from [32P]orthophosphate labeled
cells, incubated in the presence (lane 2) or absence (lane 3) of the CDK1/2
inhibitor Roscovitine (50 M), separated by SDS-PAGE, and subjected to
autoradiography (32P) or immunoblotting (IB) with anti-FLAG antibody. Im-
munoprecipitation of cells transfected with empty vector was performed as
control (lane 1). C, upper panel, shown is the kinetics of G1-S phase progres-
sion of MCF-7 cells transfected with empty vector (dashed black line) or ex-
pressing wild-type RBP1 (solid black line) after cells were arrested in G0/G1
phase by ICI 182780 treatment and stimulated with estradiol to synchro-
nously re-enter cell cycle. Cells were stained with BrdU and harvested at the
indicated times to determine the percentage of BrdU-positive cells. Error
bars represent S.E of three independent experiments. Lower panel, FLAG-
RBP1 expressed in [32P]orthophosphate-labeled MCF-7 cells, subjected to
the same treatment as in the upper panel, was immunoprecipitated from
G0/G1 phase-arrested cells (time 0 h; lane 2, ICI) or at 27 h after estradiol
addition when cells were in S phase (time 27 h, lane 3, ICI E2). The im-
munoprecipitates were separated by SDS-PAGE and subjected to autora-
diography (32P) or immunoblotting with anti-FLAG antibody (IB) to deter-
mine loading. Immunoprecipitation of cells transfected with empty vector
was performed as control (lane 1). This experiment is representative of two
independent experiments.
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phosphorylated GST-RBP1784–1257 (Fig. 3A, lanes 2 and 3).
Similarly, when the GST-RBP1784–1257His6-SAP30 complex
was preassembled and subsequently incubated with cyclin
A/CDK2, phosphorylation of GST-RBP1784–1257 did not af-
fect the level of binding of His6-SAP30 (Fig. 3B). Therefore,
CDK-mediated phosphorylation of RBP1 did not alter its af-
finity for SAP30 in vitro.
CDK-mediated Phosphorylation of RBP1 Does Not Impact
on Its Interaction with or Alter SAP30mSin3AHDAC-associ-
ated activity in Vivo—We next assessed if the association or
activity of the SAP30mSin3AHDAC complex is altered in
immunoprecipitates of RBP1 fromMCF-7 cells arrested in
G0/G1 phase or those in S phase, when RBP1 phosphorylation
is increased (Fig. 1C). To perform these studies, MCF-7 cells,
which express wild-type pRb (58), were transiently trans-
fected with pCMV Tag2A-RBP1 to ectopically express FLAG-
RBP1. MCF-7 cells were arrested in G0/G1 phase of the cell
and stimulated to synchronously re-enter the cell cycle, as
described in Fig. 1C. Immunoprecipitation of FLAG-RBP1
revealed that the levels of bound SAP30 and mSin3A re-
mained unaltered between cells in G0/G1 (ICI) or S phase
(ICI E2) (Fig. 3C, lanes 3 and 4).
It is possible that CDK-mediated phosphorylation of RBP1
may alter the activity of the SAP30mSin3HDAC complex
through allosteric mechanisms without altering the subunit
composition. To evaluate this possibility and quantitatively
assess the levels of RBP1-associated SAP30mSin3HDAC ac-
tivity, RBP1 immunoprecipitates from lysates of G0/G1 or S
phase MCF-7 cells were assayed for associated HDAC activ-
ity. These results showed the same level of RBP1-associated
HDAC activity fromMCF-7 cells in G0/G1 or S phase of the
cell cycle (Fig. 3D). Altogether, the in vitro and in vivo studies
indicate that CDK-mediated phosphorylation of RBP1 does
not impact on its interaction with nor alter the activity of the
associated SAP30mSin3HDAC complex.
CDK-mediated Phosphorylation of RBP1 and pRb Disrupts
Their Interaction in Vitro—Because CDK-mediated phos-
phorylation of RBP1 did not alter its interaction with
FIGURE 2. RBP1 is phosphorylated on serines 864 and 1007 in vivo and in vitro by cyclin A/CDK2. A, shown is phosphoamino acid analysis of GST-RBP1
phosphorylated in vitro by cyclin A/CDK2 in the presence of [-32P]ATP (left panel) or immunoprecipitated FLAG-RBP1 metabolically labeled with
[32P]orthophosphate in HEK293 cells in vivo (right panel). The positions of phosphoserine (p-Ser), phosphothreonine (p-Thr), and phosphotyrosine (p-Tyr) are
marked by arrows. B, tandemmass spectrometry spectra of FLAG-RBP1 immunoprecipitated from HEK293 cell lysates is shown. (i) RBP1 859–867 (parent
ion, 583.8m/z 2) shows phosphorylation at S864. (ii) RBP1 1004–1017 (parent ion, 785.37m/z) shows phosphorylation at S1007. (iii) RBP1 1103–1122 (par-
ent ion, 711.0m/z 3) shows phosphorylation at Ser-1109. AMU, atomicmass units. C, purified recombinant His6-RBP1
784–930 (left panel) and His6-RBP1
937–1073
(right panel) and their corresponding alanine mutants His6-RBP1
784–930 (S864A) and His6-RBP1
937–1073 (S1007A) were incubated in the absence () or
presence () of cyclin A/CDK2 and [-32P]ATP. After SDS-PAGE, the proteins were visualized by autoradiography (upper panels) and Coomassie Blue (lower
panels). D, shown is a schematic representation of the domain organization of RBP1 and the position of the three phosphorylation sites (underlined) identi-
fied by mass spectrometry. Ser-864 and -1007, which conform to CDK consensus phosphorylation sites, are marked by black circles, whereas a gray circle
marks Ser-1109. The asterisk denotes phosphorylation sites identified on endogenous RBP1 in phosphoproteomic studies (56, 57). The LVCHE motif (amino
acids 957–961) responsible for binding to the pocket of pRb is indicated. The Tudor, ARID, and Chromo domains and the repressor regions 1 and 2 of RBP1
are indicated. Repressor region 2 binds to SAP30.
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SAP30mSin3HDAC, we next tested if the interaction with
pRb was affected. RBP1 binds to the pocket region of pRb via
an LXCXE motif (23), which is present in many pRb binding
proteins (29). The CDK phosphorylation site serines 864 and
1007 flank the LXCXE pRb binding motif (amino acids 957–
961) (Fig. 2D). We established an in vitro RBP1-pRb binding
assay, where recombinant MBP-pRb279–928 containing the
pRb pocket region was incubated with GST-RBP1. Briefly,
MBP-pRb was captured on amylose resin, which was washed
extensively before detection of bound RBP1 by immunoblot-
ting with anti-GST antibody. GST-RBP1 specifically bound to
MBP-pRb279–928 (Fig. 4A, lane 4). To determine whether this
interaction is sensitive to phosphorylation, we phosphorylated
GST-RBP1 and/or MBP-pRb279–928 with cyclin A/CDK2 be-
fore the binding reaction. Phosphorylation of GST-RBP1 with
cyclin A/CDK2 reduced its level of binding to unphosphory-
lated MBP-pRb279–928 by40% compared with the level of
binding observed when both proteins were unphosphorylated
(Fig. 4A, lanes 4 and 5, upper panel). Conversely, phosphory-
lation of MBP-pRb279–928 reduced its binding to unphosphor-
ylated GST-RBP1 by75% (Fig. 4A, lanes 4 and 6, upper
panel). However, when both proteins were phosphorylated by
A/CDK2, the GST-RBP1MBP-pRb279–928 interaction was
maximally reduced (85%) (Fig. 4A, lanes 4 and 7, upper
panel). Omitting ATP from the phosphorylation reactions
before the binding assay did not affect the binding of GST-
RBP1 to MBP-pRb279–928, demonstrating that the observed
changes were due to phosphorylation by cyclin A/CDK2 (Fig.
4A, lanes 4–7, lower panel).
We next tested if cyclin A/CDK2-mediated phosphoryla-
tion disrupts a preassembled GST-RBP1MBP-pRb279–928
complex. We mixed both unphosphorylated proteins to form
a complex as described under “Experimental Procedures.”
The amylose resin-bound GST-RBP1MBP-pRb279–928 com-
plex was then incubated either in the absence or presence of
cyclin A/CDK2 under phosphorylation conditions followed by
washing of the resin and immunoblotting for bound GST-
RBP1 with anti-GST antibody. Compared with the control
unphosphorylated GST-RBP1MBP-pRb279–928,35% less
GST-RBP1 was bound to MBP-pRb279–928 when the GST-
RBP1MBP-pRb279–928 complex was phosphorylated by
A/CDK2 (Fig. 4B). Altogether, these studies demonstrate that
A/CDK2-mediated phosphorylation of both RBP1 and pRb
disrupts their association in vitro.
FIGURE 3. CDK-mediated phosphorylation of RBP1 does not impact on its interaction with SAP30 in vitro or affect associated SAP30mSin3AHDAC
activity in vivo. A, cyclin A/CDK2-mediated phosphorylation of GST-RBP1 does not affect binding to SAP30 in vitro. Upper panel, GST-RBP1784–1257 immobi-
lized on glutathione-agarose was either unphosphorylated (lane 2) or phosphorylated with cyclin A/CDK2 (lane 3) and incubated with purified recombinant
His6-SAP30 to assess binding, as described under “Experimental Procedures.” The level of His6-SAP30 binding was assessed by immunoblotting with anti-
His antibody. As a control, His6-SAP30 was incubated with empty glutathione agarose (lane 1). Lower panel, in vitro kinase assay confirming phosphorylation
of purified GST-RBP1784–1257 with cyclin A/CDK2 [-32P]ATP (lane 2). B, preformed GST-RBP1784–1257His6-SAP30 complex was incubated in the absence
(lane 1) or presence of cyclin A/CDK2 (lane 2) under phosphorylation conditions and then washed to remove unbound His6-SAP30. The level of His6-SAP30
bound to GST-RBP1784–1257 was assessed by immunoblotting with anti-His antibody. C, the levels of RBP1-associated SAP30 and mSin3A do not change
during G0/G1-S phase cell cycle progression. FLAG-RBP1 was immunoprecipitated from either exponentially growing (lane 1), G0/G1-arrested with ICI
182780 (lane 3, ICI), or S phase (27 h after the addition of estradiol to ICI 182780-arrested cells) (lane 4, ICI E2) MCF-7 cells. The immunoprecipitates were
assessed for the levels of FLAG-RBP1 and co-immunoprecipitating SAP30 and mSin3A by immunoblotting with the appropriate antibodies. Lane 2 repre-
sents control immunoprecipitates from cells transfected with empty vector. Lower panel, the histograms represent the relative levels of SAP30 (left) and
mSin3A (right) bound to the immunoprecipitated FLAG-RBP1 from G0/G1-arrested (ICI) cells or cells in S phase (ICI E2). Error bars representS.E of three
independent experiments. D, RBP1-associated HDAC activity does not change during progression from G0/G1 (ICI) into S phase (ICI E2). FLAG-RBP1 was
immunoprecipitated fromMCF-7 cells arrested in G0/G1 or in S phase, as described in C. Immunoprecipitates were then incubated with [
3H]acetylhistones
in the absence or presence of the HDAC inhibitor trichostatin A (TSA, 3 M) to perform HDAC assays, as described under “Experimental Procedures.” The
graph represents the means S.E. of three independent experiments. Immunoprecipitates were subjected to immunoblotting with anti-FLAG antibody to
demonstrate RBP1 loading (lower panel, lanes 2–4).
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RBP1 Dissociates from pRb as Cells Progress from G0/G1
into S phase of the Cell Cycle—We next assessed if CDK-me-
diated phosphorylation of RBP1 and pRb leads to their disso-
ciation in vivo. To perform these studies, MCF-7 cells were
transiently transfected with pCMV Tag2A-RBP1 and RBP1
immunoprecipitated from cells in either G0/G1 phase (ICI) or
S phase (ICI E2) of the cell cycle, as described in Figs. 1C
and 3C. We monitored the phosphorylation status of pRb,
which changes substantially when cells progress from G0/G1
phase, where CDK activity is low and pRb is hypophosphory-
lated, into S phase, where cyclin DCDK4/6, cyclin ECDK2,
and cyclin ACDK2 complexes are active and hyperphosphor-
ylate pRb (8). Hyperphosphorylated pRb migrates slower
than hypophosphorylated pRb on SDS-PAGE (8). Lysate pre-
pared from an asynchronous culture of exponentially growing
MCF-7 cells contains both hypo- and hyperphosphorylated
forms of pRb (Fig. 4C, upper panel, lane 1), reflective of cells
in various phases of the cell cycle. In G0/G1 phase, pRb was
largely hypophosphorylated due to low CDK activity, whereas
the majority of pRb was hyperphosphorylated and migrated
slower on SDS-PAGE, when the MCF-7 cells were in S phase
(Fig. 4C, upper panel, lanes 2 and 3). To assess the RBP1 in-
teraction with pRb in vivo and its dependence on the phos-
phorylation status of RBP1 and pRb, we immunoprecipitated
FLAG-RBP1 fromMCF-7 cells that were asynchronous, G0/
G1-arrested or in S phase. Immunoblotting the FLAG-RBP1
immunoprecipitates for associated pRb revealed that RBP1
bound almost exclusively to the hypophosphorylated form of
pRb, strongly suggesting that the interaction is phosphoryla-
tion-sensitive (Fig. 4C, middle panel, lanes 2–4). Further-
more,2.5-fold more pRb was associated with RBP1 in
G0/G1 phase-arrested cells when CDK is low, compared with
cells in S phase, when CDK activity is high (Fig. 4C,middle
panel, lanes 3 and 4). These results are consistent with our in
vitro findings showing that cyclin A/CDK2-mediated phos-
phorylation promotes dissociation of RBP1 and pRb. Alto-
FIGURE 4. CDK-mediated phosphorylation of RBP1 and pRb induces their dissociation in vitro and in vivo during G0/G1-S phase cell cycle progres-
sion. A, cyclin A/CDK2-mediated phosphorylation of RBP1 and pRb disrupts their association in vitro. Purified recombinant MBP-pRb279–928 immobilized on
amylose resin was either unphosphorylated (pRb279–928, lanes 4 and 5) or phosphorylated with cyclin A/CDK2 (pRb279–928-(P), lanes 6 and 7). The samples
were then incubated with either unphosphorylated GST-RBP1 (RBP1, lanes 4 and 6) or cyclin A/CDK2-phosphorylated GST-RBP1 (RBP1-(P), lanes 5 and 7),
and binding was performed as described under “Experimental Procedures.” The level of GST-RBP1 binding was assessed by immunoblotting with anti-GST
antibody (upper panel). As controls, unphosphorylated (lane 2) or phosphorylated GST-RBP1 (lane 3) was incubated with empty amylose resin. To demon-
strate that changes in association between RBP1 and pRb were phosphorylation-dependent, ATP was omitted from the phosphorylation reactions (lanes
4–7, lower panel). Lane 1 represents 10% of the input of GST-RBP1 in the binding reaction. B, cyclin A/CDK2-mediated phosphorylation disrupts preformed
RBP1pRb complex in vitro. Pre-formed MBP-pRb279–928GST-RBP1 complex immobilized on amylose resin was incubated in the absence (lane 1) or presence
of cyclin A/CDK2 (lane 2) under phosphorylation conditions and then washed. Bound GST-RBP1 was assessed by immunoblotting with anti-GST antibody.
C, the level of RBP1-associated with pRb decreases as cells progress from G0/G1 to S phase of the cell cycle. Upper panel, lysates from either exponentially
growing (lane 1), G0/G1 phase-arrested with ICI 182780 (lane 2, ICI), or S phase (27 h after the addition of estradiol to ICI 182780-arrested cells) (lane 3, ICI
E2) MCF-7 cells were subjected to Western blotting with an anti-pRb antibody to demonstrate relative levels of hypophosphorylated and hyperphosphory-
lated pRb.Middle panel, FLAG-RBP1 was immunoprecipitated (IP) from either exponentially growing (lane 2), G0/G1 phase arrested with ICI 182780 (lane 3,
ICI), or S phase (27 h after the addition of estradiol to ICI 182780-arrested cells) (lane 4, ICI E2) MCF-7 cells. Lane 1 represents control vector transfected
cells. The immunoprecipitates were assessed for the levels of FLAG-RBP1 and co-immunoprecipitating pRb by immunoblotting with the appropriate anti-
bodies. Lower panel, the histograms represent the relative levels of pRb bound to the immunoprecipitated FLAG-RBP1 from G0/G1 arrested (ICI) or cells in S
phase (ICI E2). Error bars represent S.E. of three independent experiments.
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gether, the in vitro and in vivo studies indicate that CDK-me-
diated phosphorylation of both RBP1 and pRb induces their
dissociation during progression from G0/G1 to S phase of the
cell cycle.
DISCUSSION
In the present study we identify the pRb-binding protein
RBP1 as a novel CDK substrate. Numerous studies have dem-
onstrated that the inhibitory function of pRb on E2F-medi-
ated transcription is inactivated by CDK-mediated phosphor-
ylation of pRb on several sites as cells progress from G1
through to S phase (13, 18, 20, 33, 34). Although the precise
mechanism underpinning this process is not entirely under-
stood, it is believed that CDK-mediated phosphorylation of
pRb on different sites changes the conformation of this pro-
tein to inhibit its binding to the E2F transactivation domain
and the SAP30mSin3HDAC complex to relieve transcrip-
tional repression. For example, cyclin D/CDK4/6-mediated
phosphorylation of serines 788 and 795 at the C terminus is
thought to destabilize the interaction with E2F (13, 20),
whereas phosphorylation of serine 567 by cyclin E/CDK2 is
thought to lead to a conformational change in the pRb pocket
to disrupt E2F binding (13). Other studies have shown that
phosphorylation of pRb threonines 356 and 373 on the inter-
domain linker (positioned between the N-terminal region and
the pocket) and serine 608 and 612 on the pocket region
linker (the spacer region located between the A and B do-
mains) by cyclin A/CDK2 or cyclin K/CDK6 significantly re-
duces the affinity of pRb for the E2F transactivation domain
(18). In addition to disrupting the interaction with E2F, phos-
phorylation of pRb threonines 821 and 826 by cyclin E/CDK2
and cyclin A/CDK2 can disrupt its interaction with HDACs to
relieve transcriptional repression (13, 20, 36).
Our results now show that in addition to phosphorylation
of pRb, concurrent CDK-mediated phosphorylation of RBP1
is important for efficient dissociation of these proteins, and
this mechanism likely underpins dissociation of the
SAP30mSin3HDAC complex from pRb as cells progress
from G1 into S phase of the cell cycle. Hence, CDK-mediated
phosphorylation of RBP1 and pRb contributed to their partial
dissociation, whereas concurrent phosphorylation of both
proteins resulted in their maximal dissociation in vitro (Fig.
4A). Consistent with these observations, examination of
RBP1/pRb association in MCF-7 cells revealed maximal asso-
ciation in G0/G1 phase-arrested cells, when CDK activity and
pRb and RBP1 phosphorylation is low (Figs. 1C and 4C). Con-
versely, as cells progressed into S phase when cyclin E/CDK2
and cyclin A/CDK2 are active and RBP1 and pRb phosphory-
lation is increased, their level of association was significantly
reduced (Fig. 4C). In contrast to the disruption of association
with pRb, CDK-mediated phosphorylation of RBP1 did not
impact on its association with SAP30 in vitro (Figs. 3, A and
B) nor did the association of RBP1 with SAP30 and mSin3 or
the associated HDAC activity vary as cells progressed from G1
to S phase in MCF-7 cells (Figs. 3, C and D). Altogether, these
data indicate that CDK-mediated phosphorylation of RBP1
and pRb disrupts their interaction to dissociate the RBP1
SAP30mSin3HDAC complex from E2F, as depicted in Fig. 5.
How phosphorylation of RBP1 and pRb leads to their disso-
ciation at a molecular level is not clear. RBP1 contains a Tu-
dor domain at the N terminus (amino acids 58–113), an
ARID domain (amino acids 314–409), a chromatin organiza-
tion modifier (Chromo) domain (amino acids 593–634), and
the LXCXE pRb binding motif (amino acids 957–961). The
RBP1 CDK phosphorylation sites (serines 864 and 1007) are
not located within any of these domains; however, they flank
the LXCXE pRb binding motif (amino acids 957–961), sug-
gesting that phosphorylation at these sites may reduce bind-
ing of the RBP1 LXCXE motif to the pRb pocket (Fig. 2D).
Previous studies have shown that CDK-mediated phosphory-
lation of pRb threonines 821 and 826 disrupts its interaction
with HDACs (13, 20, 36), suggesting that phosphorylation of
these pRb sites in addition to RBP1 phosphorylation contrib-
FIGURE 5. CDK-mediated cumulative phosphorylation of pRb and concurrent phosphorylation of RBP1 promotes their dissociation tomediate re-
lease of the SAP30mSin3HDAC complex. During G0/G1 phase, when CDK activity is low, the RBP1/pRb interaction mediates HDAC-dependent pRb inhi-
bition on E2F transcription factors. As cells progress into the cell cycle, G1 and S phase CDKs phosphorylate both pRb and RBP1 to disrupt their interaction,
removing SAP30mSin3HDACs from pRb and E2F and thereby allowing transcription of genes necessary for S phase cell cycle progression.
CDK-mediated Phosphorylation of RBP1
5116 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286•NUMBER 7•FEBRUARY 18, 2011
 at Queensland Univ of Technology (CAUL) on M
ay 11, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
utes to their dissociation. The importance of concurrent
CDK-mediated phosphorylation of RBP1 and pRb is exempli-
fied in preliminary studies in our laboratory, investigating if
phosphorylation of RBP1 is important for cell cycle progres-
sion. We generated RBP1 phosphosite mutants, where serines
864 and 1007 were mutated to alanine (RBP1-Ala) or aspar-
tate residues (RBP1-Asp) to potentially mimic constitutively
unphosphorylated and phosphorylated RBP1, respectively.
Studies of the G1-S cell cycle progression in MCF-7 cells ec-
topically expressing wild-type RBP1, RBP1-Ala, or RBP1-Asp
as described in Fig. 1C revealed similar kinetics of cell cycle
progression (data not shown). Because maximal RBP1/pRb
dissociation and abrogation of pRb inhibition toward E2F is
achieved by CDK phosphorylation of both proteins on differ-
ent sites, perturbation of the cell cycle progression likely re-
quires simultaneous co-expression of phosphosite mutants of
both RBP1 and pRb. It will be important to identify the rele-
vant phosphorylation sites on pRb that regulate dissociation
from RBP1 to perform these studies. In addition, further stud-
ies of the pRbRBP1 complex will be required to provide spe-
cific structural information on this interaction and how phos-
phorylation of specific sites mediates the dissociation of these
proteins. For example, x-ray crystallography studies on the
association of the pRb C-terminal region with E2F have pro-
vided insights into how CDK-mediated phosphorylation of
pRb contributes to E2F release (18, 20).
Our data expand on the existing understanding on the im-
portance of cumulative CDK-mediated phosphorylation in
regulating pRb function to control cell cycle progression.
Multiple phosphorylations in controlling cell cycle regulators
are emerging as a mechanism for setting a threshold for sub-
strate regulation and commitment to cell cycle progression.
For example, in Saccharomyces cerevisiae the CDK inhibitor
Sic1 must be degraded to allow activation of S phase CDKs
and cell cycle progression (59, 60). Efficient Sic1 ubiquitina-
tion by the SkpCullinF-box ubiquitin ligase complex leading
to its proteasomal degradation and cell cycle progression is
dependent on phosphorylation on multiple sites by G1 phase
CDKs, which sets a phosphorylation threshold. This ensures
establishment of a G1 phase period that can only be overcome
when G1-phase CDKs reach a critical threshold leading to
rapid Sic1 phosphorylation and degradation (61). Our data
suggest a similar paradigm, where the cumulative and concur-
rent CDK-mediated phosphorylation of pRb and RBP1 sets a
higher phosphorylation threshold for efficient dissociation of
the SAP30mSin3HDAC complex from E2F, thus ensuring
cells only commit to cell cycle progression when cyclin/CDK
activity is high.
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